The two companies are merging after previously filing for bankruptcy due to opioid-related litigation and financial losses.

Immunotherapy pioneer Mark Frohlich, MD, CEO of Indapta Therapeutics, discusses the promise of harnessing natural killer cells to reshape treatment for cancer and autoimmune disease.

The joint venture with generative AI firm Hologen hands MeiraGTx $200 million up front as well as other financial perks — a “transformative” deal, according to the company’s CEO.

A day after announcing a business split-off to focus on weight loss and diabetes implants, Vivani Medical has implanted the first patient with its device.

The merger will give the combined entity the financial flexibility to pursue drug licensing deals and broaden its therapeutic focus, executives said on a conference call.

Emergent has entered a strategic financial investment agreement with Swiss Rockets to support the latter’s biotech portfolio.

A look at the current landscape and how young companies can set the stage for product launch.

Whilst showing promise in cancer therapies, lead-212-based alpha emitters are hard to commercially supply.

Vivace Therapeutics has closed $35m in a Series D financing round to support the clinical development of its cancer drug VT3989.

Jonathon Whitton, AuD, PhD, VP, auditory global program head, Regeneron, discusses regulatory challenges for DB-OTO, Regeneron’s AAV-based gene therapy for hearing loss.

Making early commercial data and analytics decisions for launch cen future-proof their data management.

Topline results from the Phase III VERITAC-2 trial found that vepdegestrant provided a statistically significant and clinically meaningful improvement in progression-free survival in patients with ER+/HER2- advanced or metastatic breast cancer.

A Harvard Business School Healthcare Alumni Association Q&A with Elaina Shekhter, EPAM’s Chief Marketing & Strategy Officer.

Dr. Dina Radenkovic, CEO of Gameto, discusses the use of iPSCs in fertility treatments, the most significant scientific hurdles they’ve encountered in developing and scaling these therapies (particularly in relation to ovarian aging), and how […]

Artiva Biotherapeutics’ CEO Fred Aslan, MD, identifies data points the company is prioritizing to demonstrate that results from certain trials will translate to similar efficacy across a range of autoimmune conditions.

The latest news for pharma industry insiders.

Atsena Therapeutics has received fast track designation from the FDA for ATSN-201, aimed at treating X-linked retinoschisis (XLRS).

Europe’s drug regulatory agency has given Kizfizo a negative opinion for the second time, following one from November 2024.

Experts weigh in on today’s life sciences leadership-development priorities critical to long-term success.

Ono Pharmaceuticals has secured the global rights to sapablursen, an RNA-targeting therapy by Ionis to treat polycythemia vera (PV).